Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
1550(c) 1546.8(c) 1547(c) 1566(c) 1581(c) Last
11 009 352 10 160 748 10 687 742 10 346 289 9 642 738 Volume
-0.95% -0.21% +0.01% +1.23% +0.96% Change
More quotes
Financials (GBP)
Sales 2019 31 814 M
EBIT 2019 8 421 M
Net income 2019 4 286 M
Debt 2019 23 222 M
Yield 2019 5,06%
Sales 2020 33 924 M
EBIT 2020 9 154 M
Net income 2020 4 734 M
Debt 2020 21 234 M
Yield 2020 5,06%
P/E ratio 2019 17,19
P/E ratio 2020 16,78
EV / Sales2019 3,20x
EV / Sales2020 2,94x
Capitalization 78 495 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (57.2%): intended for respiratory diseases (40.5% of net sales), HIV infection (25.2%), immune system disorders (2.2%) ) and other (32.1%); - OTC and... 
Sector
Pharmaceuticals
Calendar
02/14Presentation
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/12GLAXOSMITHKLINE : Mylan launches Advair generic at one-third price
RE
02/08World's largest wealth fund to press firms for climate data at AGMs
RE
02/07ASTRAZENECA : Drugmakers say UK could lose out on EU anti-counterfeit drugs push
RE
02/07LONDON MARKETS: London Markets Slip Into The Red As Bank Of England Warns Of ..
DJ
02/07GLAXOSMITHKLINE : Initial Safety Surveillance on Shingrix Consistent With Clinic..
AQ
02/07GLAXOSMITHKLINE : Glaxo Shifts Its Focus to Cancer Drugs
DJ
02/06LONDON STOCK EXCHANGE : FTSE breaks six-day winning streak, fire burns Ocado
RE
02/06GLAXOSMITHKLINE : Glaxo Focuses on Cancer Drugs to Restock Pipeline
DJ
02/06GLAXOSMITHKLINE : Profits at GSK boosted by sales of shingles vaccine
RE
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
02/15WSJ TAX GUIDE 2019 : The Drug Industry -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 16,4  GBP
Spread / Average Target 3,7%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE5.02%101 206
JOHNSON & JOHNSON4.08%360 216
PFIZER-3.85%243 426
ROCHE HOLDING LTD.11.22%230 883
NOVARTIS6.02%225 234
MERCK AND COMPANY3.31%205 274